Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

Trial Profile

Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs AGEN 2034 (Primary)
  • Indications Cervical cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Agenus
  • Most Recent Events

    • 05 Jun 2018 Results of escalating dose cohorts (n=30) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 17 May 2018 According to an Agenus media release, data will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 03 Aug 2017 According to an Agenus media release, the company expects to complete dose-escalation for monotherapy, define optimal combination dose and collect safety and receptor occupancy data and recruit patients with second line cervical cancer in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top